Guizhou Bailing Group Pharmaceutical Co Ltd
Guizhou Bailing Group Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells medicines in China. It operates through four segments: Industrial, Commerce, Medical institutions, and Others The company offers medicines in various forms, including tablets, capsules, granules, syrups, powders, pills, dews, pastes, sprays, and oral liquids, as well as wines … Read more
Market Cap & Net Worth: Guizhou Bailing Group Pharmaceutical Co Ltd (002424)
Guizhou Bailing Group Pharmaceutical Co Ltd (SHE:002424) has a market capitalization of $961.92 Million (CN¥7.06 Billion) as of March 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #8371 globally and #1572 in its home market, demonstrating a -0.39% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Guizhou Bailing Group Pharmaceutical Co Ltd's stock price CN¥5.05 by its total outstanding shares 1397598400 (1.40 Billion).
Guizhou Bailing Group Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Guizhou Bailing Group Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $4.65 Billion to $961.92 Million (-13.38% CAGR).
Guizhou Bailing Group Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Guizhou Bailing Group Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.19x
Guizhou Bailing Group Pharmaceutical Co Ltd's market cap is 0.19 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
21.81x
Guizhou Bailing Group Pharmaceutical Co Ltd's market cap is 21.81 times its annual earnings
10.35x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $4.65 Billion | $1.90 Billion | $411.37 Million | 2.45x | 11.31x |
| 2016 | $3.45 Billion | $2.21 Billion | $482.33 Million | 1.56x | 7.16x |
| 2017 | $2.82 Billion | $2.59 Billion | $526.14 Million | 1.09x | 5.36x |
| 2018 | $1.61 Billion | $3.14 Billion | $563.24 Million | 0.51x | 2.86x |
| 2019 | $1.62 Billion | $2.85 Billion | $282.75 Million | 0.57x | 5.72x |
| 2020 | $1.49 Billion | $3.09 Billion | $152.38 Million | 0.48x | 9.79x |
| 2021 | $1.45 Billion | $3.11 Billion | $118.48 Million | 0.47x | 12.22x |
| 2022 | $1.55 Billion | $3.54 Billion | $138.47 Million | 0.44x | 11.22x |
| 2023 | $1.54 Billion | $4.26 Billion | -$414.51 Million | 0.36x | N/A |
| 2024 | $733.35 Million | $3.83 Billion | $33.62 Million | 0.19x | 21.81x |
Competitor Companies of 002424 by Market Capitalization
Companies near Guizhou Bailing Group Pharmaceutical Co Ltd in the global market cap rankings as of March 19, 2026.
Key companies related to Guizhou Bailing Group Pharmaceutical Co Ltd by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Guizhou Bailing Group Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Guizhou Bailing Group Pharmaceutical Co Ltd's market cap moved from $4.65 Billion to $ 961.92 Million, with a yearly change of -13.38%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥961.92 Million | +16.09% |
| 2025 | CN¥828.59 Million | +12.99% |
| 2024 | CN¥733.35 Million | -52.53% |
| 2023 | CN¥1.54 Billion | -0.61% |
| 2022 | CN¥1.55 Billion | +7.37% |
| 2021 | CN¥1.45 Billion | -2.94% |
| 2020 | CN¥1.49 Billion | -7.77% |
| 2019 | CN¥1.62 Billion | +0.30% |
| 2018 | CN¥1.61 Billion | -42.83% |
| 2017 | CN¥2.82 Billion | -18.30% |
| 2016 | CN¥3.45 Billion | -25.82% |
| 2015 | CN¥4.65 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Guizhou Bailing Group Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $961.92 Million USD |
| MoneyControl | $961.92 Million USD |
| MarketWatch | $961.92 Million USD |
| marketcap.company | $961.92 Million USD |
| Reuters | $961.92 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.